Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lymphoma, T-Cell, Peripheral 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Leukemia, Myeloid, Acute 6Lymphoma, T-Cell, Cutaneous 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lung Neoplasms 4Hodgkin Disease 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Sarcoma 3Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoblastic Lymphadenopathy 3Fallopian Tube Neoplasms 3Burkitt Lymphoma 3Thyroid Neoplasms 2

Interventions

lutetium Lu 177 dotatate 40Everolimus 35Magnetic Resonance Spectroscopy 15lanreotide 14gallium Ga 68 dotatate 13Temozolomide 13Octreotide 12Nivolumab 12pembrolizumab 11Capecitabine 11surufatinib 10177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Sunitinib 8Specimen Handling 7Carboplatin 7telotristat ethyl 6pasireotide 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Lutetium-177 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Ipilimumab 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × belinostat × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡